Return of the metabolic trajectory to the original area after human bone marrow mesenchymal stem cell transplantation for the treatment of fulminant hepatic failure

Journal of Proteome Research
Jun LiLanjuan Li

Abstract

Our recent study first demonstrated that human bone marrow mesenchymal stem cell (hBMSC) transplantation could prevent death from fulminant hepatic failure (FHF) in pigs. To further clarify the metabolic mechanism of hBMSC transplantation in FHF, the plasma collected from FHF pigs that received transplantation of hBMSCs was examined using metabolic analysis to identify the key molecular markers that regulate recovery. The results showed that obvious metabolic disturbance occurred during FHF, whereas the hBMSC transplantation group showed less severe liver injury. The metabolic trajectory returns to its original state at week 3 following the hBMSC transplantation. In total, the concentration of 26 metabolites, including conjugated bile acids, phosphatidylcholines, lysophosphatidylcholines, fatty acids, amino acid and sphingomyelin, are significantly different between the FHF group and the hBMSC transplantation group. Moreover, the time course of changes in the metabolites corresponded with that of the biochemical and histological analyses. Real-time PCR further confirmed that the gene expression of phospholipase A1, lecithin-cholesterol acyltransferase and lysophosphatidylcholine acyltransferase 1 decreased significantly, wherea...Continue Reading

References

Jan 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J H HoofnagleN Ascher
Mar 29, 2000·Journal of Hepatology·J O ClemmesenP Ott
May 26, 2004·Journal of Hepatology·Ira J Fox, Jayanta Roy-Chowdhury
Aug 10, 2006·Molecular and Cellular Biochemistry·Nambi AiyarStephen A Douglas
May 22, 2007·The Journal of Nutrition·Cornelis H C DejongSteven W M Olde Damink
Nov 29, 2007·Stem Cells and Development·Gabriela G CezarAlysson R Muotri
Jan 12, 2008·Biochimica Et Biophysica Acta·Michael Oertel, David A Shafritz
Jan 24, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Man Jeong PaikGwang Lee
Jul 3, 2009·Atherosclerosis·Gerd Schmitz, Katharina Ruebsaamen
Jan 28, 2010·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Eleanor S Gilchrist, John N Plevris
Apr 27, 2010·Experimental Hematology·Graça Almeida-PoradaChristopher D Porada
May 4, 2010·Nature Chemical Biology·Oscar YanesGary Siuzdak
Feb 23, 2011·International Journal of Molecular Sciences·Gregory S Richmond, Terry K Smith
Oct 25, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Qi Wang, Yi-Jun Wu
Nov 15, 2011·Biochemical and Biophysical Research Communications·Hitoshi HasegawaMasaki Yasukawa
Mar 17, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jun LiLanjuan Li

❮ Previous
Next ❯

Citations

Oct 20, 2015·Trends in Molecular Medicine·Bruno ChristSandra Winkler
Aug 26, 2018·Stem Cell Research & Therapy·Yong-Hong WangHong Tang
Jun 15, 2019·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Chenxia Hu, Lanjuan Li
Nov 7, 2019·Journal of Cellular and Molecular Medicine·Chenxia HuLanjuan Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs
Jun LiJi-Fang Sheng
Magyar sebészet
Imre Fehérvári
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Alexander Koch, Christian Trautwein
© 2021 Meta ULC. All rights reserved